Gestational trophoblastic disease (GTD) is a rare group of pregnancy-related disorders that originate from abnormal growth of cells in the placenta. It encompasses a spectrum of conditions, including hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor.
The prevalence of GTD varies across different populations and regions. Globally, it is estimated that GTD affects approximately 1 in every 1,000 to 2,000 pregnancies. However, the incidence can be significantly higher in certain geographical areas, such as Southeast Asia, where rates of up to 1 in every 100 pregnancies have been reported.
Hydatidiform mole, the most common form of GTD, has a prevalence of around 1 in every 600 to 1,000 pregnancies worldwide. This condition occurs when the placenta develops abnormally, leading to the formation of a mass of cysts instead of a healthy fetus.
While GTD is relatively rare, it is crucial to diagnose and treat it promptly. Early detection and appropriate management can significantly improve outcomes for affected individuals.